Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Integrated BioPharma Inc. (INBP : OTC)

• Company Description    Integrated BioPharma, Inc. is a well-established biopharma company serving the varied needs of the nutraceutical, biotech and pharmaceutical industries. Through a number of wholly owned subsidiaries INB develops, manufactures and distributes, worldwide over 130 products. Number of Employees: 134

• Price / Volume Information    Yesterday's Closing Price: $0.17 Daily Weekly Monthly 20 Day Moving Average: 17,653 shares Shares Outstanding: 30.98 (millions) Market Capitalization: $5.42 (millions) Beta: 0.50 52 Week High: $0.42 52 Week Low: $0.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.41% -4.41% 12 Week 9.38% 6.71% Year To Date -50.70% -55.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 225 LONG AVENUE BUILDING 15 - HILLSIDE,NJ 07205 USA ph: 888-319-6962 fax: 973-926-1735 investors@ibiopharma.com http://www.ibiopharma.com

• General Corporate Information    Officers Christina Kay - Co-Chief Executive Officer and Director Riva Sheppard - Co-Chief Executive Officer and Director Dina L. Masi - Chief Financial Officer Robert Canarick - Director Damon DeSantis - Director Peer Information Integrated BioPharma Inc. (GSAC) Integrated BioPharma Inc. (CASIF) Integrated BioPharma Inc. (ALCD.) Integrated BioPharma Inc. (OMNN) Integrated BioPharma Inc. (CGPI.) Integrated BioPharma Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45811V105 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 30.98 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $5.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.31 Price/Cash Flow: - Price / Sales: 0.12 EPS Growth vs. Year Ago Period: -300.00% vs. Previous Quarter: -33.33% Sales Growth vs. Year Ago Period: -30.89% vs. Previous Quarter: -3.08% ROE 09/30/26 - - 06/30/26 - -14.78 03/31/26 - -8.32 ROA 09/30/26 - - 06/30/26 - -11.24 03/31/26 - -6.57 Current Ratio 09/30/26 - - 06/30/26 - 3.00 03/31/26 - 3.25 Quick Ratio 09/30/26 - - 06/30/26 - 1.42 03/31/26 - 1.78 Operating Margin 09/30/26 - - 06/30/26 - -6.48 03/31/26 - -3.43 Net Margin 09/30/26 - - 06/30/26 - -6.48 03/31/26 - -3.43 Pre-Tax Margin 09/30/26 - - 06/30/26 - -5.84 03/31/26 - -2.32 Book Value 09/30/26 - - 06/30/26 - 0.57 03/31/26 - 0.61 Inventory Turnover 09/30/26 - - 06/30/26 - 4.77 03/31/26 - 5.07 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.38 03/31/26 - 0.42

Powered by Zacks Investment Research ©